The Prometheus League
Breaking News and Updates
- Abolition Of Work
- Ai
- Alt-right
- Alternative Medicine
- Antifa
- Artificial General Intelligence
- Artificial Intelligence
- Artificial Super Intelligence
- Ascension
- Astronomy
- Atheism
- Atheist
- Atlas Shrugged
- Automation
- Ayn Rand
- Bahamas
- Bankruptcy
- Basic Income Guarantee
- Big Tech
- Bitcoin
- Black Lives Matter
- Blackjack
- Boca Chica Texas
- Brexit
- Caribbean
- Casino
- Casino Affiliate
- Cbd Oil
- Censorship
- Cf
- Chess Engines
- Childfree
- Cloning
- Cloud Computing
- Conscious Evolution
- Corona Virus
- Cosmic Heaven
- Covid-19
- Cryonics
- Cryptocurrency
- Cyberpunk
- Darwinism
- Democrat
- Designer Babies
- DNA
- Donald Trump
- Eczema
- Elon Musk
- Entheogens
- Ethical Egoism
- Eugenic Concepts
- Eugenics
- Euthanasia
- Evolution
- Extropian
- Extropianism
- Extropy
- Fake News
- Federalism
- Federalist
- Fifth Amendment
- Fifth Amendment
- Financial Independence
- First Amendment
- Fiscal Freedom
- Food Supplements
- Fourth Amendment
- Fourth Amendment
- Free Speech
- Freedom
- Freedom of Speech
- Futurism
- Futurist
- Gambling
- Gene Medicine
- Genetic Engineering
- Genome
- Germ Warfare
- Golden Rule
- Government Oppression
- Hedonism
- High Seas
- History
- Hubble Telescope
- Human Genetic Engineering
- Human Genetics
- Human Immortality
- Human Longevity
- Illuminati
- Immortality
- Immortality Medicine
- Intentional Communities
- Jacinda Ardern
- Jitsi
- Jordan Peterson
- Las Vegas
- Liberal
- Libertarian
- Libertarianism
- Liberty
- Life Extension
- Macau
- Marie Byrd Land
- Mars
- Mars Colonization
- Mars Colony
- Memetics
- Micronations
- Mind Uploading
- Minerva Reefs
- Modern Satanism
- Moon Colonization
- Nanotech
- National Vanguard
- NATO
- Neo-eugenics
- Neurohacking
- Neurotechnology
- New Utopia
- New Zealand
- Nihilism
- Nootropics
- NSA
- Oceania
- Offshore
- Olympics
- Online Casino
- Online Gambling
- Pantheism
- Personal Empowerment
- Poker
- Political Correctness
- Politically Incorrect
- Polygamy
- Populism
- Post Human
- Post Humanism
- Posthuman
- Posthumanism
- Private Islands
- Progress
- Proud Boys
- Psoriasis
- Psychedelics
- Putin
- Quantum Computing
- Quantum Physics
- Rationalism
- Republican
- Resource Based Economy
- Robotics
- Rockall
- Ron Paul
- Roulette
- Russia
- Sealand
- Seasteading
- Second Amendment
- Second Amendment
- Seychelles
- Singularitarianism
- Singularity
- Socio-economic Collapse
- Space Exploration
- Space Station
- Space Travel
- Spacex
- Sports Betting
- Sportsbook
- Superintelligence
- Survivalism
- Talmud
- Technology
- Teilhard De Charden
- Terraforming Mars
- The Singularity
- Tms
- Tor Browser
- Trance
- Transhuman
- Transhuman News
- Transhumanism
- Transhumanist
- Transtopian
- Transtopianism
- Ukraine
- Uncategorized
- Vaping
- Victimless Crimes
- Virtual Reality
- Wage Slavery
- War On Drugs
- Waveland
- Ww3
- Yahoo
- Zeitgeist Movement
-
Prometheism
-
Forbidden Fruit
-
The Evolutionary Perspective
Monthly Archives: June 2021
Mr. Daniel C. Montano, CEO, is recognized as Biotech Entrepreneur of the Year and Dr. Marc – GlobeNewswire
Posted: June 18, 2021 at 7:37 am
LAS VEGAS, June 17, 2021 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (a private company) (Zhittya or the Company), is proud to announce that Mr. Daniel C. Montano, CEO, and founder of Zhittya Genesis Medicine Inc. has received the award of Biotech Entrepreneur of the Year from the Nevada Biotechnology & Health Science Consortium. We also congratulate Dr. Marc Kahn, Dean of the Kirk Kerkorian School of Medicine at the University of Nevada, Las Vegas (UNLV), for receiving the Medical Professional of the Year Award from the same institution.
The Nevada Biotechnology & Health Science Consortium (NevBio) was founded in 2007 to encourage the development and expansion of the Health Sciences and Biotechnology in Southern Nevada. NevBio is part of the national biotechnology association, the Biotechnology Innovation Organization (BIO) and the Council of Bioscience Associations. Thousands of people have attended the monthly presentations sponsored by NevBio over the last 14 years on topics such as immunotherapy, nuclear medicine, gene editing, sepsis, cancer, C-Diff, pain, biofilm, angiogenesis, clinical trials, patents, raising capital, and much more. NevBio has given legislative advice both in Carson City & Washington DC, on assisting the development of health sciences in Southern Nevada. Senator Harry Reid and the late Nevada Chancellor Jim Rogers have spoken at the award dinners.
Daniel C. Montano, CEO of Zhittya Genesis Medicine Inc., is a biotech pioneer leading the creation of a revolutionary biopharmaceutical treatment termed Therapeutic Angiogenesis and is the recipient of the Biotech Entrepreneur of the Year Award. Daniel Montano moved to Las Vegas in 2002 from California to advance biotechnology here. Therapeutic Angiogenesis has demonstrated in US FDA clinical trials that it can trigger the growth of new blood vessels, thereby treating heart disease, the number one cause of death in the world. In animal experiments, monkeys given experimental Parkinsons disease, then treated with Therapeutic Angiogenesis, reversed their disease progression. Heart disease, strokes, peripheral artery disease, Parkinsons disease, multiple sclerosis and Alzheimers disease are all diseases he is applying Therapeutic Angiogenesis to treat. If successful, Las Vegas could become the biotech center of the world for Regenerative Medicine through Therapeutic Angiogenesis.
Dr. Marc Kahn will be awarded the Medical Professional of the Year, as the Dean of the new Kirk Kerkorian School of Medicine. Dr. Kahns experience is in both medicine and teaching medical professionals the business of medicine. His introduction of a joint MD-MBA program was very well received. His leadership of the School of Medicine is critical to the long-term success of making Las Vegas a biomedical center.
The Las Vegas Valley is developing into a biomedical center, with three medical schools and biotech companies that have either started here or have moved here from California. Biotech and health science companies are moving to Las Vegas to take advantage of its low costs, world-class airport, and hospitality facilities. The Las Vegas Valleys population has grown to almost 2.8 million people and is still growing. The Awards Dinner will be on Thursday, July 15th at 6 pm at the Ahern Hotel in Las Vegas. Register at nevbio.org.
The Awards Dinner will be:
Contact Information: Daniel Montano, CEO Zhittya Genesis Medicine, Inc. Phone: (1) 702-790-9980 E-mail: dan@zhittyamedicine.com Website: zgm.care
Go here to read the rest:
Mr. Daniel C. Montano, CEO, is recognized as Biotech Entrepreneur of the Year and Dr. Marc - GlobeNewswire
Posted in Gene Medicine
Comments Off on Mr. Daniel C. Montano, CEO, is recognized as Biotech Entrepreneur of the Year and Dr. Marc – GlobeNewswire
Taysha Gene Therapies to Participate in Upcoming Investor Healthcare Conference and CEO Forum – Business Wire
Posted: at 7:37 am
DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in virtual fireside chats at the LifeSci Genetics Medicine Conference and LSX Biotech Growth CEO Forum.
Conferences Details:
Event:
LifeSci Genetics Medicine Conference
Date:
Tuesday, June 22, 2021
Time:
10:00 am ET
Format:
Fireside chat
Participants:
RA Session II, President, Founder and CEO
Dr. Suyash Prasad, Chief Medical Officer and Head of R&D
Kamran Alam, Chief Financial Officer
Event:
LSX Biotech Growth CEO Forum
Topic:
Too Much of a Good Thing Can be Wonderful: Optimizing Value From Broad Discovery Platforms Through Strategy and Strategic Partnering
Date:
Tuesday, June 22, 2021
Time:
1:10 pm ET
Format:
Fireside chat
Participants:
RA Session II, President, Founder and CEO
Webcasts for these conferences will be available in the Events & Media section of the Taysha corporate website at https://ir.tayshagtx.com/news-events/events-presentations. Archived versions of the webcasts will be available on the website for 60 days.
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our teams proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platforman engine for potential new cureswith a goal of dramatically improving patients lives. More information is available at http://www.tayshagtx.com.
Posted in Gene Medicine
Comments Off on Taysha Gene Therapies to Participate in Upcoming Investor Healthcare Conference and CEO Forum – Business Wire
Scientists Demonstrate Promising New Approach for Treating Cystic Fibrosis | Newsroom – UNC Health and UNC School of Medicine
Posted: at 7:37 am
Scientists led by UNC School of Medicine researchers Silvia Kreda, PhD, and Rudolph Juliano, PhD, created an improved oligonucleotide therapy strategy with the potential for treating other pulmonary diseases, such as COPD and asthma.
CHAPEL HILL, NC UNC School of Medicine scientists led a collaboration of researchers to demonstrate a potentially powerful new strategy for treating cystic fibrosis (CF) and potentially a wide range of other diseases. It involves small, nucleic acid molecules called oligonucleotides that can correct some of the gene defects that underlie CF but are not addressed by existing modulator therapies. The researchers used a new delivery method that overcomes traditional obstacles of getting oligonucleotides into lung cells.
As the scientists reported in the journal Nucleic Acids Research, they demonstrated the striking effectiveness of their approach in cells derived from a CF patient and in mice.
With our oligonucleotide delivery platform, we were able to restore the activity of the protein that does not work normally in CF, and we saw a prolonged effect with just one modest dose, so were really excited about the potential of this strategy, said study senior author Silvia Kreda, PhD, an associate professor in the UNC Department of Medicine and the UNC Department Biochemistry & Biophysics, and a member of the Marsico Lung Institute at the UNC School of Medicine.
Kreda and her lab collaborated on the study with a team headed by Rudolph Juliano, PhD, Boshamer Distinguished Professor Emeritus in the UNC Department of Pharmacology, and co-founder and Chief Scientific Officer of the biotech startup Initos Pharmaceuticals.
About 30,000 people in the United States have CF, an inherited disorder in which gene mutations cause the functional absence of an important protein called CFTR. Absent CFTR, the mucus lining the lungs and upper airways becomes dehydrated and highly susceptible to bacterial infections, which occur frequently and lead to progressive lung damage.
Treatments for CF now include CFTR modulator drugs, which effectively restore partial CFTR function in many cases. However, CFTR modulators cannot help roughly ten percent of CF patients, often because the underlying gene defect is of the type known as a splicing defect.
CF and splicing defects
Splicing is a process that occurs when genes are copied out or transcribed into temporary strands of RNA. A complex of enzymes and other molecules then chops up the RNA strand and re-assembles them, typically after deleting certain unwanted segments. Splicing occurs for most human genes, and cells can re-assemble the RNA segments in different ways so different versions of a protein can be made from a single gene. However, defects in splicing can lead to many diseases including CF when CFTRs gene transcript is mis-spliced.
In principle, properly designed oligonucleotides can correct some kinds of splicing defects. In recent years the U.S. Food and Drug Administration has approved two splice switching oligonucleotide therapies for inherited muscular diseases.
In practice, though, getting oligonucleotides into cells, and to the locations within cells where they can correct RNA splicing defects, has been extremely challenging for some organs.
It has been especially difficult to get significant concentrations of oligonucleotides into the lungs to target pulmonary diseases, Kreda said.
Therapeutic oligonucleotides, when injected into the blood, have to run a long gauntlet of biological systems that are designed to keep the body safe from viruses and other unwanted molecules. Even when oligonucleotides get into cells, the most usually are trapped within vesicles called endosomes, and are sent back outside the cell or degraded by enzymes before they can ever do their work.
A new delivery strategy
The strategy developed by Kreda, Juliano, and their colleagues overcomes these obstacles by adding two new features to splice switching oligonucleotides: Firstly, the oligonucleotides are connected to short, protein-like molecules called peptides that are designed to help them to distribute in the body and get into cells. Secondly, there is a separate treatment with small molecules called OECs, developed by Juliano and Initos, which help the therapeutic oligonucleotides escape their entrapment within endosomes.
The researchers demonstrated this combined approach in cultured airway cells from a human CF patient with a common splicing-defect mutation.
Adding it just once to these cells, at a relatively low concentration, essentially corrected CFTR to a normal level of functioning, with no evidence of toxicity to the cells, Kreda said.
The results were much better with than without OECs, and improved with OEC dose.
There is no mouse model for splicing-defect CF, but the researchers successfully tested their general approach using a different oligonucleotide in a mouse model of a splicing defect affecting a reporter gene. In these experiments, the researchers observed that the correction of the splicing defect in the mouse lungs lasted for at least three weeks after a single treatment hinting that patients taking such therapies might need only sporadic dosing.
The researchers now plan further preclinical studies of their potential CF treatment in preparation for possible clinical trials.
Yan Dang, Catharina van Heusden, Veronica Nickerson, Felicity Chung, Yang Wang, Nancy Quinney, Martina Gentzsch, and Scott Randell were other contributors to this study from the Marsico Lung Institute; Ryszard Kole a co-author from the UNC Department of Pharmacology.
The Cystic Fibrosis Foundation and the National Institutes of Health supported this work.
Media contact: Mark Derewicz, UNC School of Medicine, 919-923-0959
Read the original post:
Scientists Demonstrate Promising New Approach for Treating Cystic Fibrosis | Newsroom - UNC Health and UNC School of Medicine
Posted in Gene Medicine
Comments Off on Scientists Demonstrate Promising New Approach for Treating Cystic Fibrosis | Newsroom – UNC Health and UNC School of Medicine
Mutations of the and gene in gastrointestinal stromal tumors among hakka population of Southern China. – Physician’s Weekly
Posted: at 7:37 am
The aim of the present study was to investigate mutation status of the cKit and PDGFRA genes in patients with a gastrointestinal stromal tumor (GIST).In total, 96 patients with a GIST were included in the study, in which polymerase chain reaction amplification and gene sequencing were used to detect the sequences of exons 9, 11, 12, 13, 14, 17, and 18 in KIT and exons 12, 14, and 18 in PDGFRA.KIT mutations were detected in 65 cases (67.71%), of which 81.54% (53/65) were located on exon 11, 12.31% (8/65) were located on exon 9, 4.61% (3/65) were located on exon 17, which included a concomitant mutation of exon 9 and 11, and 4.08% (2/65) were located on exon 13, which included a concomitant mutation on exon 11. The most common mutation in exon 11 was deletion, which accounted for 77.36% (41/53) of the cases, followed by a point mutation observed in 22.64% (12/53) of the cases. Among the 31 GIST cases without a KIT mutation, a mutation in PDGFRA was detected in 5 cases (5.21%, 5/96; 16.13%, 5/31). With respect to gender, age, tumor max diameter, tumor position, and mitotic index, there were no significant differences between KIT/PDGFRA mutations and non-mutations.GIST mainly occurs in the stomach, and the cytological morphology is mainly spindle cells, and the mutations mainly occur in KIT genes. We need a large sample size to analyze the regularity of GIST gene mutations in Hakka population and understand the independent prognostic correlation of all KIT/PDGFRA genotypes.
Originally posted here:
Mutations of the and gene in gastrointestinal stromal tumors among hakka population of Southern China. - Physician's Weekly
Posted in Gene Medicine
Comments Off on Mutations of the and gene in gastrointestinal stromal tumors among hakka population of Southern China. – Physician’s Weekly
GENECAST begins clinical research on early diagnosis of lung cancer with Samsung Medical Center – GlobeNewswire
Posted: at 7:37 am
SEOUL, Korea, June 14, 2021 (GLOBE NEWSWIRE) -- On June 14, GENECAST (CEO, SeungChan Baek), a specialist in liquid biopsy-based cancer diagnostics, announced that it will begin a clinical study for the early diagnosis of non-small cell lung cancer (NSCLC). The team will be led by Professor Jhingook Kim in the Lung and Esophageal Surgery Division within the Department of Thoracic Surgery at Samsung Medical Center.
This study evaluates whether the results of liquid biopsy-based EGFR testing with GENECAST's ADPS technology can represent the results of EGFR testing on tumor tissue DNA. This study is especially significant for identifying the clinical effects of liquid biopsies on early cancer detection, given that it involves early-stage cancer patients at the 1B to 3A clinical stages.
To date, the clinical effects of liquid biopsies applied to lung cancer patients have mostly been researched with a focus on lung cancer that has been systemically spread through blood. In other words, lung cancer containing a portion of multiple tumor cells in the blood. On other hand, little research has been done about the power to detect EGFR gene mutations before surgery in patients with lung cancer that is resectable due to the absence of lesions spread through blood. This is because carrying out this research is considerably difficult.
In recent years, active discussions have globally been under way over the possibility of researching the pre-surgical administration of EGFR inhibitors for resectable early-stage lung cancer. This is because the pre-surgical administration of EGFR inhibitors is expected to not only enable surgery by blocking the spread of tumors in early stages and reducing the size of tumors, but also increase the actual survival rate of patients. In addition, it is easier to administrate drugs before surgery. Using EGFR inhibitors should be preceded by the diagnosis of EGFR gene mutations, but traditional biopsies often involve high risks or are impossible due to the nature of sites of lung cancer.
If the clinical effects of liquid biopsies with ADPS technology prove that this diagnostic method can detect early-stage NSCLC, then it is expected that this will lead to more active research efforts on the administration of EGFR inhibitors in these early-stage patients.
GENECAST's chief technical officer (CTO) Byungchul Lee ph.D commented, "With the recent FDA approval of Osimertinib as an adjuvant therapy for early-stage NSCLC, the early diagnosis of this cancer using liquid biopsies is receiving attention again. If liquid biopsies can diagnose not only metastatic lung cancer, but also operatable early-stage lung cancer, then they are likely to improve the survival rates of NSCLC patients."
Professor Jhingook Kim, a specialist in lung cancer in the Department of Thoracic Surgery at Samsung Medical Center, expressed his expectations for this study: "The study is very significant in terms of identifying the effects of liquid biopsies on early-stage patients considering resective surgery for a complete recovery, not patients with systemic metastases. Depending on the study results, follow-up studies will likely be conducted on various topics such as the use of liquid biopsies in the early diagnosis of cancer.
# Overview of GENECAST
GENECAST is a specialist in liquid biopsy-based cancer diagnostics that analyze cancer genes. This company has achieved 0.01% of actual detection sensitivity and the highest sensitivity of 0.0001% through its own original technology called the Allele-Discriminating Priming System (ADPS). ADPS is a qPCR-based technology that provides simpler and faster testing than other liquid biopsy-based diagnostic methods. It enables the analysis of cancer genes in Stage 1 cancer patients by realizing the highest detection sensitivity available today. GENECAST is operating a range of businesses including precision medicine, LDT commercialization, and companion diagnostics based on ADPS technology, and is dedicated to the development of new technologies that can realize early diagnostics according to the type of cancer. More information can be found at http://www.igenecast.com.
Contact:
Soobin ShinGENECAST Press OfficeTel: +82-2-2157-3151E-mail: comm@genecast.co.kr
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/96d91465-1699-41a3-89f2-6be43bf58df5
Excerpt from:
GENECAST begins clinical research on early diagnosis of lung cancer with Samsung Medical Center - GlobeNewswire
Posted in Gene Medicine
Comments Off on GENECAST begins clinical research on early diagnosis of lung cancer with Samsung Medical Center – GlobeNewswire
Evonik collaborating with Stanford University on ‘next generation’ of mRNA-based medicine – BioPharma-Reporter.com
Posted: at 7:37 am
The two entities are looking to expand the potential applications of mRNA therapeutics to tackle a range of diseases.
The delivery of mRNA effectively and safely into the cell is one of the biggest challenges for expanding the use of mRNA therapeutics to promising fields such as cancer immunotherapy, protein replacement and gene editing.
The German company said a polymer-based delivery system was developed at the US university and complements its own technology platform for mRNA delivery. Known as ChargeAlteringReleasableTransporters (CART), the system was developed by Professor Robert Waymouth, Professor Paul Wender and Professor Ronald Levy.
Starting this month, Evonik and Stanford scientists will begin a three-year sponsored research collaboration to develop CART, which Evonik will license and commercialize.
Through this project we look forward to enabling the next generation of mRNA-based medicine, said Dr Thomas Riermeier, head of Evoniks Healthcare business line.
Evonik said its team will work together with Stanford University scientists to scale up the synthesis and formulation, and further develop its innovative technology for organ selective delivery based on a non-animal-derived, synthetic degradable polymer.
Evonik said it is aiming to make this technology GMP quality and available for use in clinical-stage developments and, ultimately, on a commercial scale.
The move is intended to expand Evoniks portfolio as a system solutions partner for advanced drug delivery.
Evonik said it recognized the potential of gene-based therapeutic approaches early on, making a targeted investment in this space with the acquisition of Transferra Nanosciences in 2016, a Vancouver-based lab with a strong focus on parenteral drug formulation development using lipid nanoparticles and liposomes.
Continued here:
Evonik collaborating with Stanford University on 'next generation' of mRNA-based medicine - BioPharma-Reporter.com
Posted in Gene Medicine
Comments Off on Evonik collaborating with Stanford University on ‘next generation’ of mRNA-based medicine – BioPharma-Reporter.com
Following the ‘Golden Rule’ is proving a political impossibility – Roll Call
Posted: at 7:35 am
A recent petition, organized by Faithful America and signed by 21,000 people, accused the bishops of weaponizing the Eucharist, and ina letterthe group thanked the more than 60 bishops who opposed the USCCB vote.Cardinal Wilton Gregory, who is archbishop of Washington, was one of them. So the president is in no danger of being turned away at a D.C. altar.
Its not a new debate, though John F. Kennedy, the first Catholic president, had to prove with words and actions that he would not let faith dictate his politics. Another famous Catholic politician,Mario Cuomo,had much to say on the subject, as he did on most everything.
In 1984, at the University of Notre Dame, no less, Cuomo, who died in 2015, said: Better than any law or rule or threat of punishment would be the moving strength of our own good example, demonstrating our lack of hypocrisy, proving the beauty and worth of our instruction.We must work to find ways to avoid abortions without otherwise violating our faith. We should provide funds and opportunity for young women to bring their child to term, knowing both of them will be taken care of if that is necessary; we should teach our young men better than we do now their responsibilities in creating and caring for human life.
That would satisfy few today. As places of worship have reopened post-pandemic, the political divide in America has followed worshippers through the doors.
Would now be the time to act on other items on Pope Francis agenda climate change, migrants, poverty, racial justice and how to ease the grief of those who lost someone or something in this harrowing year?
More:
Following the 'Golden Rule' is proving a political impossibility - Roll Call
Posted in Golden Rule
Comments Off on Following the ‘Golden Rule’ is proving a political impossibility – Roll Call
No Time Runs against the King (IRS): The Golden Creditor Rule and its Discontents – JD Supra
Posted: at 7:35 am
[co-authors: Emma Wheeler, and Alex Xiao]
A bankruptcy court in North Carolina recently joined a growing number of courts allowing debtors and trustees to avoid prepetition transactions using the IRSs lookback period of ten years, rather than the applicable state statute of limitations period.1 In In re Zagaroli, the Western District of North Carolina bankruptcy court found that a trustee could step into the shoes of the IRS for the purposes of avoiding a transfer under section 544(b), therefore utilizing the longer reach-back period available to the IRS. No. 18-50508, 2020 Bankr. LEXIS 3111 (Bankr. W.D.N.C., Nov. 3, 2020). In this post, we discuss not only the Zagaroli case, but also the relevant arguments surrounding the split among courts on this issue.
The Debtor, Peter Lawrence Zagaroli, filed a chapter 7 bankruptcy petition in May 2018. Approximately seven years prior, the Debtor allegedly transferred several pieces of real property to his parents for no consideration. The trustee sought to avoid these transfers, which occurred while Mr. Zagaroli was insolvent, pursuant to section 544(b) of the bankruptcy code.
Section 544(b), also known as the golden creditor rule, allows a trustee to step into the shoes of any unsecured creditor to avoid any transfer the creditor could avoid under applicable law. Most states have adopted a uniform voidable transactions act that provides a statute of limitations for avoiding transfers. Under applicable North Carolina law, the statute of limitations is four years.
In this case, the trustee sought to use the IRS, which held an unsecured claim, as its golden creditor in an attempt to invoke the Internal Revenue Code as applicable law. The Internal Revenue Code, under section 26 U.S.C. 6502, provides a ten-year period for collecting a tax.
The court, using a plain language reading of 544(b), held that the trustee could step into the shoes of the IRS to avoid the transfers under the Internal Revenue Code. The court agreed with the majority view that applicable law should be broadly construed to encompass the Internal Revenue Code, which the IRS could have used to recover outside of bankruptcy.
In so holding, the court rejected the transferees arguments that 544(b) does not grant the trustee the power to bring actions that are grounded in tax evasion claims that are only available to the United States outside of the bankruptcy arena and that a trustee should not be able to take advantage of the immunity of the United States from the state statutes of limitation. The court found these arguments unpersuasive, noting that the transferees position would leave both the trustee and the IRS without recourse to avoid transfers it would otherwise be entitled to avoid outside of bankruptcy.
The holding of In re Zagaroli is hardly a surprise since a majority of bankruptcy courts ruling on this issue has reached the same conclusion. However, given that no circuit court has yet to address the issue, further discussion is warranted on whether the debtor or trustee can use the IRS as the golden creditor and what arguments parties have made in court so far.
The common law tradition has historically granted a longer statute of limitations to sovereign than private actors. An ancient doctrine known as nullum tempus occurrit regi, or no time runs against the king, was recognized by the U.S. Supreme Court in United States v. Summerlin, where the Court held that the United States is not bound by state statutes of limitations or subject to the defense of laches in enforcing its rights. 310 U.S. 414, 416 (1940). The modern rationale behind this rule, as articulated by the Ninth Circuit, is that public rights, revenues, and property should not be forfeited due to the negligence of public officials. S.E.C. v. Rind, 991 F.2d 1486, 1491 (9th Cir. 1993). This historic principle is the foundation that allows the Internal Revenue Service to preempt state law statute of limitations and be bound only by the Internal Revenue Codes statute of limitations.
The issue then, in the 544(b) context, becomes whether the trustee can utilize the IRSs preemption power to gain a longer claw back period. Absent a decision from the circuit level, the most notable bankruptcy court decision disapproving of the IRS as the golden creditor is In re Vaughan. 498 B.R. 297 (Bankr. D.N.M. 2013). The Vaughan court denied a trustees request to avoid an alleged fraudulent transfer that happened beyond the states 5-year statute of limitations but within that of the IRS, an unsecured creditor in the case.
The Vaughan courts holding relied on two arguments. First, the nullum tempus doctrine does not apply because the bankruptcy trustee is not sovereign and its actions do not protect the public interest. Second, because the IRS holds unsecured claims in a substantial portion of bankruptcy cases, allowing the trustee to step into the shoes of the IRS would practically render the state statutes of limitations moot. Id. at 305. The Vaughan court found that Congress could not have intended this policy consequence.
A number of courts have since addressed and rejected these two arguments. See e.g., In re Gaither, 595 B.R. 201 (Bankr. D.S.C. 2018), In re Kipnis, 555 B.R. 877 (Bankr. S.D. Fla. 2016), and Hillen v. City of Many Trees (In re CVAH, Inc), 570 B.R. 816 (Bankr. D. Idaho 2017). The Kaiser court, for example, rejected the Vaughan courts nullum tempus analysis by pointing out that 544(b) has always provided a derivative right to the trustee. Ebner v. Kaiser (In re Kaiser), 525 B.R. 697, 713 (Bankr. N.D. Ill. 2014). For these courts, first, it is not material whether the trustee is sovereign, because trustees only exercise the rights on behalf of the IRS, who may rightfully preempt state law pursuant to the Internal Revenue Code. Similarly, a majority of courts have dismissed the Vaughan courts second, policy-oriented argument granting the IRS golden creditor status by citing the unambiguous plain language of 544(b), as in Zagaroli.
Another argument against using the IRS as the golden creditor is that the practice could potentially lead to an unlimited claw back period. See In re CVAH, Inc., 570 B.R. at 838. The 10-year statute of limitations constraining the IRS only starts to run after the taxpayer files a tax return. Because the taxpayer could theoretically delay filing the tax return for an unlimited period, the IRS and the trustee could avoid transactions for an unlimited reach-back period.
Courts have also dismissed this concern. The CVAH court noted that timeliness is only one element of a constructive fraudulent transfer claim. Id. at 838. Practically, the burden to prove the claim likely would become more onerous for the trustee the further back in time the transfer occurred from the bankruptcy petition date.
Although no circuit court has addressed the golden creditor rule with regard to the IRS, the Western District of North Carolina bankruptcy court joins an increasing number of bankruptcy courts in holding that applicable law under 544(b) includes the Internal Revenue Code and its 10-year statute of limitations.
It is also worth noting that when clawing back transactions in the shoes of the IRS, the trustee or the debtor can recover more than the amount that was owed to the IRS. At least one court found that the trustee could use the IRS as the golden creditor even where the IRSs claims were paid in full after the commencement of the bankruptcy case. See In re Greater Se. Cmty. Hosp. Corp. I, 365 B.R. at 301. Therefore, in cases where the IRS holds an unsecured claim, the majority courts application of the golden creditor rule significantly increases the statute of limitations period that a debtor or transferee must analyze for clawing back transactions into the bankruptcy estate. Parties that engage in transactions with distressed companies or companies that become distressed will be exposed to a much wider window of potentially avoidable transactions. Since the IRS is so frequently a creditor in bankruptcy cases, decisions allowing a debtor or trustee to use the IRS as a golden creditor threaten to greatly expand the universe of transactions susceptible to avoidance. It remains to be seen, however, whether any circuit court will take up this issue or contradict the majority rule of the bankruptcy courts.
1 See, e.g., Vieira v. Gaither (In re Gaither), 595 B.R. 201 (Bankr. D.S.C. 2018); Mukamal v. Citibank (In re Kipnis), 555 B.R. 877 (Bankr. S.D. Fla. 2016); Ebner v. Kaiser (In re Kaiser), 525 B.R. 697 (Bankr. N.D. Ill. 2014); Alberts v. HCA Inc. (In re Greater Se. Cmty. Hosp. Corp. I), 365 B.R. 293 (Bankr. D.D.C. 2006); Shearer v. Tepsic (In re Emergency Monitoring Technologies, Inc.), 347 B.R. 17 (Bankr. W.D. Pa. 2006); Osherow v. Porras (In re Porras), 312 B.R. 81 (Bankr. W.D. Tex. 2004).
Continue reading here:
No Time Runs against the King (IRS): The Golden Creditor Rule and its Discontents - JD Supra
Posted in Golden Rule
Comments Off on No Time Runs against the King (IRS): The Golden Creditor Rule and its Discontents – JD Supra
Tips to make a perfect and successful Resume – Onrec
Posted: at 7:35 am
What exactly is a resume?
So, basically a resume is a one or two pager professional as well as career document that outlines the complete work history, the complete volunteership, the complete as well as detailed internship experience, a complete series of skills a person posses, as well as the educational background that is required in the most of the job applications by the employer.
As per the experts as well as authentic sources, a resume is seen as an opportunity to build a potential as well as successful career of a person. Moreover, a resume is also considered a chance to show off all of the great experience as well as the skills of a person to a potential employer. Moreover, a resume is also considered a great chance to make a structured outline of all of your skills as well as capabilities in one single point place.
So, basically a resume should be self communicative, which means a resume should be something that is self explanatory and need not to be explained. Moreover, a person should try to include as best information as possible to get the particular job the person is looking as well as applying for. The resume of the person should also be concise as well as precise in nature. Moreover, a resume should be no longer than one or two page maximum as well as a resume should not include any kind of the wordy language in the format. A golden rule for resume is to be detailed but along being with brief.
A resume should be very easy to read and understand, which means it should be made like a resume can be scanned over a glance. Always avoid including unnecessary things as well as always make things easy to understand as well as find. Always mention the most important as well as necessary things in starting as well as the work down from there. Always keep the font size as well as font or we can say writing font same throughout the resume so that it can look good. However, the name of the person as well as the proper contact info should always be mentioned at the top of the resume only.
1. Proofreading every thing very much thoroughly is one of the major Do points for a successful as well as professional resume.
2. The resume should be grammatically correct as well as full-proof is one of the major Do points for a successful as well as professional resume.
3. Getting professional advice to make a resume is one of the major Do points for a successful as well as professional resume.
4. Seek advice for the resume is one of the major Do points for a successful as well as professional resume.
1. Do not include unnecessary information is one of the major Dont points for a successful as well as professional resume.
2. Do not include unnecessary references in the resume is one of the major Dont points for a successful as well as professional resume.
3. Do not include unnecessary skills in the resume like internet surfing and all is one of the major Dont points for a successful as well as professional resume.
To see an example of the resume you can visit link resume-example.com.
1. Contact Info is one of the major sections that are to be included there in the successful as well as professional resume.
All the perfect as well as professional resumes must include the contact information like phone number, email address, proper name, linkedin address, etc. so that the employer can connect with the person and get in touch with them. However, the email address mentioned in the resume should look professional and does not include the crazy names in the email address.
2. Objective is one of the major sections that are to be included there in the successful as well as professional resume.
As per the industry experts the objective should be short as well as concise, along with it the objective must be customized as per the specific organization as well as position.
3. Work Experience is one of the major sections that are to be included there in the successful as well as professional resume.
All the relevant jobs must be listed in the resume, aloing with all the internships, as well as all the volunteer experience wherever the person have worked.
4. Education is one of the major sections that are to be included there in the successful as well as professional resume.
Education in the resume should include all the degrees that a person have earned as well as that are in the process of earning along with the proper names as well as their levels. Moreover, education in the resume should compulsorily mention the names of the majors as well as minors.
5. Skills is one of the major sections that are to be included there in the successful as well as professional resume.
Skills to be mentioned in the resume like Computer software proficiency like the skills of Microsoft Excel, Adobe Photoshop, different types of the Languages, computer languages, skills, hardware knowledge for a computer science or all types of certification.
6. Honors and Awards is one of the major sections that are to be included there in the successful as well as professional resume.
Read the original:
Posted in Golden Rule
Comments Off on Tips to make a perfect and successful Resume – Onrec
This is Your Neighbor: JoAnn McCoy | Opinion | emissourian.com – The Missourian
Posted: at 7:35 am
JoAnn (Peters) McCoy is a lifelong resident of Washington. As a kid, she worked on entering art in every category at the Town & Country Fair fine arts building and was voted Most Creative at St. Francis Borgia Regional High School.
A year after graduating from Borgia, she began her career with Mary Kay. She has earned several company cars and in 1996 became sales director. Her more rewarding career was in the family sign business, Jim Peters Signs, which lasted over 35 years . She served as president for almost 20 years before retiring.
Presently, McCoy is enjoying the Mary Kay business and operating the Room For Art Gallery in downtown Washington, which features more than 30 area artists. She wed her husband, Andy McCoy, in 2006. He is a professional drag race car builder and driver, and she enjoys watching him race.
When I was a kid, I wanted to be an artist and a cowgirl. I always wanted a horse, but my parents wouldnt let me until I was 12.
What would you rather be doing right now? Seeing the spectacular Grand Canyon.
Shh! Dont tell anyone that it was me dressed in armor as the St. Francis Borgia Knight riding my horse when a touchdown was scored.
Other than your wedding day and/or the birth of your children, what was your proudest moment? Seeing my husband drive the 1957 car he built, drag race at an NHRA event and going 245 mph in a quarter-mile in 6.2 seconds.
It really stinks when people smoke and use foul language.
What word in the dictionary would your face be next to? Entrepreneur.
I always laugh My husband calls me out when a strange foreign accent flows out like Im from another country.
Invite any three people, living or dead, to dinner. Who are they? What would you serve? Jesus, James and Peter. Ill serve carryout. Since I dont cook, my three choices are frozen, microwave and takeout.
At the end of a really long day at work, I like to eat popcorn.
People who knew me in high school thought I was a good parade float-builder.
My most unforgettable brush with greatness was reaching the top 2 percent of Mary Kay as an independent sales director.
I would drop all my plans tonight if I had the chance to go on a nature trail walk or bike ride.
If someone gave me a million dollars, there is still no way I would keep it all myself. Its so important to share blessings.
America should be more concerned about being united.
Im OK if theres ever a national shortage of alcohol.
When Im in a bookstore, I always go to this section first: Bookmarks, like what I have at Room For Art Gallery.
What is the most useful piece of advice you have ever received? Keep your life in balance. Faith first, family second, career third.
When Im cruising down the road, Im likely listening to Christian music or Katrina and the Waves Walking on Sunshine.
I always get sentimental when good deeds are done unexpectedly.
The older I get, the more I realize time is so precious, so I try to cram in all I can in my half days. I like doing something productive 9 a.m. to 9 p.m.
If I had one do-over I would have kept my hugger orange 1969 Camaro.
My favorite item of clothing is an artful top, plus clothe myself with compassion, kindness, humility, gentleness and patience.
If Ive learned anything at all The golden rule: Do unto others as you would have them do unto you.
What do you wish Washington or Franklin County had to offer? A Honey Baked Ham store.
Who is your personal hero or mentor? My parents, Jim and Betty Peters.
A historical figure Id like to meet is: Abraham Lincoln.
In my opinion there is no more beautiful place on Earth than the beach.
Ill watch the movie anytime it is on television: Titanic.
Whats your superpower? Staying positive, uplifting encouragement.
If you could know the absolute and total truth to one question, what question would you ask? How long will I live here on Earth?
More here:
This is Your Neighbor: JoAnn McCoy | Opinion | emissourian.com - The Missourian
Posted in Golden Rule
Comments Off on This is Your Neighbor: JoAnn McCoy | Opinion | emissourian.com – The Missourian







